AG
AVDL

Aperio Group’s Avadel Pharmaceuticals AVDL Stock Holding History

Aperio Group’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-10,371
Closed -$76K – 2259
2018
Q1 		$76K Sell
10,371
-6,559
-39% -$57.7K ﹤0.01% 2227
2017
Q4 		$139K Buy
+16,930
New +$159K ﹤0.01% 2186

Other funds holding AVDL

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Aperio Group's AVDL Position: Q2 2018 in Review

Aperio Group sold out of Avadel Pharmaceuticals (AVDL) in Q2 2018, closing a stake of 10,371 shares — an estimated $76K sold.

Aperio Group first reported a position in AVDL in Q4 2017 and held it in 2 quarters. The position peaked at $139K in Q4 2017. 75 funds tracked by Wall St. Rank hold AVDL as of Q2 2018.

  • Aperio Group reported no remaining Avadel Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Aperio Group sold 10,371 Avadel Pharmaceuticals shares in Q2 2018, an estimated $76K.
  • Aperio Group first reported a position in Avadel Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • Aperio Group's Avadel Pharmaceuticals position peaked at $139K in Q4 2017.
  • 75 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2018.

Based on Aperio Group's 13F filing for Q2 2018, filed 30 Jul 2018.